Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer

Necchi, Andrea; Cucchiara, Vito; Grivas, Petros; Bratslavsky, Gennady; Jacob, Joseph M.; Spiess, Philippe E.; Sokol, Ethan S.; Killian, Jonathan Keith; Lin, Douglas I.; Ramkissoon, Shakti; Huang, Richard S.P.; Madison, Russell; Venstrom, Jeffrey M.; Schrock, Alexa B.; Danziger, Natalie; Decker, Brennan; Gjoerup, Ole; Graf, Ryon P.; Oxnard, Geoffrey R.; Tukachinsky, Hanna; Ross, Jeffrey S.

doi:10.1002/cncr.33865

Cited by 7 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HRR gene alterations are truncal, as they originate in primary tumor specimens, and frequency does not increase with treatment or upon disease progression. [20][21][22] Our analysis supports that the vast majority of HRR gene alterations were found in primary archived tumor specimens, supporting that these alterations are truncal and archived specimens can be used for CGP.…”

Section: Discussionsupporting

confidence: 73%

“…CGP results from tissue and liquid specimens in our analysis (see Figure, Table 3, and Supplemental Figures 1 and 2, https://www.urologypracticejournal.com) found gene alteration and biomarker frequencies that are consistent with published literature. 18,20-23,28 Of note, SPOP was only found in tissue specimens. SPOP mutations are more frequent in primary tumors compared to metastatic sites and are mutually exclusive from TRMPRSS2-ERG rearrangements.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influencing Best Practices for Genomic and Germline Testing in Urology

Shore,

Scott,

Srivastava

et al. 2023

Urology Practice

View full text Add to dashboard Cite

Introduction:We evaluated germline and somatic testing practices and compared results from tissue and liquid biopsy specimens in a large community urology setting.Methods:A retrospective analysis was performed on advanced prostate cancer patients from a single community practice between June 2016 and September 2021. Clinical data and sequencing results from tissue and liquid biopsy specimens were available for 389 patients. Genomic data were available for 81 tissues and 74 liquid biopsy specimens. Comparison of genomic findings included 81 tissues and 27 liquid biopsy specimens. The number of actionable biomarkers and patients screened and enrolled in clinical trials was assessed from germline and somatic testing. Frequency of pathogenically altered genes, alteration types, and biomarkers were assessed from tissue and liquid specimens. Alteration frequency was compared between specimen types for the top 25 altered genes.Results:Clinically relevant alterations were found from germline and somatic testing in both tissue and liquid biopsy specimens. The frequency of microsatellite instability-high, tumor mutational burden-high, or alterations in homologous recombination repair genes was consistent with published findings. Concordance between tissue and liquid findings varied with low circulating tumor DNA.Conclusions:Germline and somatic testing is critical for treatment decisions and should be standard of care for community practices. Liquid biopsy is a viable alternative when circulating tumor DNA is high.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 99%

Influencing Best Practices for Genomic and Germline Testing in Urology

Shore,

Scott,

Srivastava

et al. 2023

Urology Practice

View full text Add to dashboard Cite

show abstract

“…Publications with the highest level of evidence were selected for review. This yielded 60 articles for which full text evaluation was performed and included in the final review 12–71 . A flow diagram of the article evaluation process is shown in Figure 1.…”

Section: Methodsmentioning

confidence: 99%

“…17 The reasons for the observed high, but imperfect concordance, also seen in other cancer types, can be varied. They likely include time between the tissue and liquid biopsies (reflecting tumor evolution, especially in late, heavily treated disease 12,25,73 ), intrapatient heterogeneity more likely to be fully captured in ctDNA than in tissue, 14,25 and a deeper analysis of the specific region of the lesion biopsied in tissue because of higher tumor fraction versus broader, lower tumor fraction analysis in ctDNA.…”

Section: Evidence Synthesis Circulating Tumor Dnamentioning

confidence: 99%

Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer

Cani

Salami²

2023

Cancer J

View full text Add to dashboard Cite

The advent of high-throughput technologies has enabled the analysis of minute amounts of tumor-derived material purified from body fluids, termed “liquid biopsies.” Prostate cancer (PCa) management, like in many other cancer types, has benefited from liquid biopsies at several stages of the disease. Although initially describing circulating tumor cells in blood, the term “liquid biopsy” has come to more prominently include cell-free, circulating tumor DNA, as well as RNA, proteins, and other molecules. They provide tumor molecular information representing the entire, often-heterogeneous disease, relatively noninvasively and longitudinally. Blood has been the main liquid biopsy specimen in PCa, and urine has also proven beneficial. Technological advances have allowed clinical implementation of some liquid biopsies in PCa, in disease monitoring and precision oncology. This narrative review introduces the main types of blood-based PCa liquid biopsies focusing on advances in the past 5 years. Clinical adoption of liquid biopsies to detect and monitor the evolving PCa tumor biology promises to deepen our understanding of the disease and improve patient outcomes.

show abstract

“…reported heterogeneity in the genomic alterations (GAs) detected in the primary tumors, metastatic sites, and ctDNA. [ 6 ]…”

Section: Disparate Genomic Profiles Of Prostate Cancer Tissue and Liquid Biopsiesmentioning

confidence: 99%